奥利司他辅助治疗对BMI≥24 kg/m^(2)PCOS患者体成分、性激素水平和促排结局的影响  

Effects of orlistat as adjuvant therapy on the body composition,sex hormones levels and ovulation induction outcomes of polycystic ovary syndrome patients with a body mass index≥24 kg/m^(2)

作　　者：徐晓杭 张凌雪 于鑫桐 赵梦思 高雪琪 于月新 XU Xiaohang;ZHANG Lingxue;YU Xintong;ZHAO Mengsi;GAO Xueqi;YU Yuexin(Department of Reproductive Medicine,Northern Theater Command General Hospital,Shenyang 111000,Liaoning,China)

机构地区：[1]北部战区总医院生殖医学科,沈阳111000

出　　处：《中国性科学》2025年第2期51-55,共5页Chinese Journal of Human Sexuality

摘　　要：目的探讨奥利司他辅助治疗体重指数(BMI)≥24 kg/m^(2)多囊卵巢综合征(PCOS)患者的疗效。方法选取2020年10月至2023年10月北部战区总医院收治的86例PCOS患者作为研究对象,按照抽签法分为对照组(43例,给予基础治疗)和研究组(43例,采用基础治疗联合奥利司他)。对比两组临床疗效、体成分指标、性激素指标、促排结局及不良反应。结果研究组治疗总有效率高于对照组(P<0.05)。治疗后,研究组体脂肪率低于对照组,腹围、内脏脂肪总面积均小于对照组(P<0.05)。治疗后,研究组总睾酮(TT)、游离睾酮(FT)水平均低于对照组(P<0.05)。两组窦卵泡计数、获卵数及不良反应发生率比较,差异无统计学意义(P>0.05)。结论BMI≥24 kg/m^(2)的PCOS患者应用奥利司他辅助治疗虽未能显著改善促排结局,但其能够改善体成分及性激素水平,安全性可靠。Objective To explore the efficacy of orlistat as an adjuvant therapy in polycystic ovary syndrome(PCOS)patients with a body mass index(BMI)≥24 kg/m^(2).Methods A total of 86 PCOS patients admitted to Northern Theater Command General Hospital from October 2020 to October 2023 were selected as the research objects and divided into control group(43 cases,received basic treatment)and study group(43 cases,received basic treatment combined with orlistat)by drawing lots method.The clinical efficacy,body composition indicators,sex hormone indicators,ovulation induction outcomes,and adverse reactions of the two groups were compared.Results The total effective rate of the research group was higher than that of the control group(P<0.05).After treatment,the body fat percentage of the study group was lower than that of the control group,and the abdominal circumference and total visceral fat area were both smaller than those of the control group(P<0.05).After treatment,the total testosterone(TT)and free testosterone(FT)levels in the study group were both lower than those in the control group.There was no statistically significant difference in the number of antral follicles,number of oocyte retrieved,and incidence of adverse reactions between the two groups(P>0.05).Conclusions Although applying orlistat as adjuvant therapy for PCOS patients with BMI≥24 kg/m^(2)does not significantly improve ovulation outcomes,but it can improve body composition and sex hormone levels,and it has reliable safety.

关 键 词：多囊卵巢综合征 奥利司他 性激素 超重 肥胖 

分 类 号：R711[医药卫生—妇产科学]